FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3123038875> ?p ?o ?g. }

• W3123038875 endingPage "270" @default.
• W3123038875 startingPage "270" @default.
• W3123038875 abstract "270 Background: To date many trials have been conducted to compare the efficacy and toxicity between TACE plus molecular targeted agents and TACE alone; all of them failed to show its clinical benefit in terms of progression free survival (PFS) or OS. In TACTICS trial (NCT01217034) TACE plus sorafenib significantly improved PFS over TACE alone in patients with unresectable HCC. ( Gut 2020;69:1374-1376). Here we will report a final OS analysis from TACTICS trial with predefined mature OS events. Methods: Patients with unresectable HCC were randomized to TACE plus sorafenib (n=80) or TACE alone (n=76). Patients in the combination group received sorafenib 400 mg once daily for 2–3 weeks before TACE, followed by 800 mg twice daily during on-demand conventional TACE sessions until time to untreatable (unTACEable) progression (TTUP), defined as untreatable tumor progression, transient deterioration to Child-Pugh C or appearance of vascular invasion/extrahepatic spread. Co-primary endpoints were progression-free survival (PFS), which is defined as TTUP, or time to any cause of death and OS. Multiplicity was adjusted by gatekeeping hierarchical testing. Results: At the cut-off date of July 31, 2020, 131 OS events were observed. Median OS was 36.2 mo with TACE plus sorafenib vs 30.8 mo with TACE alone (HR, 0.861 [95%CI, 0.607, 1.223]; P=0.40). ΔOS was 5.4 mo. Updated PFS was 22.8 mo with TACE plus sorafenib vs 13.5 mo with TACE alone (HR, 0.661[95%CI, 0.466, 0.938]; P=0.02). Post-trial treatments with active procedures/agents were observed in 47 (58.8%) in TACE plus sorafenib and in 58 (76.3%) with TACE alone. Anticancer procedures in TACE alone group include resection/ablation in 14, transarterial therapy in 53 and radiation in 7. Anticancer medications in TACE alone include targeted agents in 40 (29 sorafenib, 5 regorafenib, 3 lenvatinib, 3 ramucirumab), other systemic chemotherapy in 5 and immunotherapy in 5. Safety was consistent with the primary analysis, with no new signals identified. Conclusion: In TACTICS, TACE plus sorafenib did not show OS benefit as compared with TACE alone although significantly better PFS was consistently observed. OS in TACE plus sorafenib in TACTICS trial showed the longest OS (36.2 mo) with the longest ΔOS (5.4 mo) as compared with the previous 5 TACE combination trials. The major reason for negative OS result was speculated that many post-trial active treatments were performed in control arm (76.3%), which implies that OS endpoint in TACE combination trial may not be feasible anymore in current era of sequential therapy with many active locoregional and systemic treatments. Clinical trial information: NCT01217034." @default.
• W3123038875 created "2021-02-01" @default.
• W3123038875 creator A5008443307 @default.
• W3123038875 creator A5013194037 @default.
• W3123038875 creator A5019395170 @default.
• W3123038875 creator A5022537134 @default.
• W3123038875 creator A5025371497 @default.
• W3123038875 creator A5027196488 @default.
• W3123038875 creator A5027724595 @default.
• W3123038875 creator A5029744979 @default.
• W3123038875 creator A5032900701 @default.
• W3123038875 creator A5033980070 @default.
• W3123038875 creator A5042770779 @default.
• W3123038875 creator A5044214575 @default.
• W3123038875 creator A5056197140 @default.
• W3123038875 creator A5061244847 @default.
• W3123038875 creator A5066924600 @default.
• W3123038875 creator A5067074178 @default.
• W3123038875 creator A5067449318 @default.
• W3123038875 creator A5076696174 @default.
• W3123038875 creator A5076725199 @default.
• W3123038875 creator A5080572816 @default.
• W3123038875 date "2021-01-20" @default.
• W3123038875 modified "2023-10-15" @default.
• W3123038875 title "TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC)." @default.
• W3123038875 doi "https://doi.org/10.1200/jco.2021.39.3_suppl.270" @default.
• W3123038875 hasPublicationYear "2021" @default.
• W3123038875 type Work @default.
• W3123038875 sameAs 3123038875 @default.
• W3123038875 citedByCount "21" @default.
• W3123038875 countsByYear W31230388752021 @default.
• W3123038875 countsByYear W31230388752022 @default.
• W3123038875 countsByYear W31230388752023 @default.
• W3123038875 crossrefType "journal-article" @default.
• W3123038875 hasAuthorship W3123038875A5008443307 @default.
• W3123038875 hasAuthorship W3123038875A5013194037 @default.
• W3123038875 hasAuthorship W3123038875A5019395170 @default.
• W3123038875 hasAuthorship W3123038875A5022537134 @default.
• W3123038875 hasAuthorship W3123038875A5025371497 @default.
• W3123038875 hasAuthorship W3123038875A5027196488 @default.
• W3123038875 hasAuthorship W3123038875A5027724595 @default.
• W3123038875 hasAuthorship W3123038875A5029744979 @default.
• W3123038875 hasAuthorship W3123038875A5032900701 @default.
• W3123038875 hasAuthorship W3123038875A5033980070 @default.
• W3123038875 hasAuthorship W3123038875A5042770779 @default.
• W3123038875 hasAuthorship W3123038875A5044214575 @default.
• W3123038875 hasAuthorship W3123038875A5056197140 @default.
• W3123038875 hasAuthorship W3123038875A5061244847 @default.
• W3123038875 hasAuthorship W3123038875A5066924600 @default.
• W3123038875 hasAuthorship W3123038875A5067074178 @default.
• W3123038875 hasAuthorship W3123038875A5067449318 @default.
• W3123038875 hasAuthorship W3123038875A5076696174 @default.
• W3123038875 hasAuthorship W3123038875A5076725199 @default.
• W3123038875 hasAuthorship W3123038875A5080572816 @default.
• W3123038875 hasConcept C126322002 @default.
• W3123038875 hasConcept C141071460 @default.
• W3123038875 hasConcept C143998085 @default.
• W3123038875 hasConcept C168563851 @default.
• W3123038875 hasConcept C203092338 @default.
• W3123038875 hasConcept C2778019345 @default.
• W3123038875 hasConcept C2778455285 @default.
• W3123038875 hasConcept C2778695046 @default.
• W3123038875 hasConcept C2780739268 @default.
• W3123038875 hasConcept C3019894029 @default.
• W3123038875 hasConcept C71924100 @default.
• W3123038875 hasConcept C90924648 @default.
• W3123038875 hasConceptScore W3123038875C126322002 @default.
• W3123038875 hasConceptScore W3123038875C141071460 @default.
• W3123038875 hasConceptScore W3123038875C143998085 @default.
• W3123038875 hasConceptScore W3123038875C168563851 @default.
• W3123038875 hasConceptScore W3123038875C203092338 @default.
• W3123038875 hasConceptScore W3123038875C2778019345 @default.
• W3123038875 hasConceptScore W3123038875C2778455285 @default.
• W3123038875 hasConceptScore W3123038875C2778695046 @default.
• W3123038875 hasConceptScore W3123038875C2780739268 @default.
• W3123038875 hasConceptScore W3123038875C3019894029 @default.
• W3123038875 hasConceptScore W3123038875C71924100 @default.
• W3123038875 hasConceptScore W3123038875C90924648 @default.
• W3123038875 hasIssue "3_suppl" @default.
• W3123038875 hasLocation W31230388751 @default.
• W3123038875 hasOpenAccess W3123038875 @default.
• W3123038875 hasPrimaryLocation W31230388751 @default.
• W3123038875 hasRelatedWork W2100869382 @default.
• W3123038875 hasRelatedWork W2179494416 @default.
• W3123038875 hasRelatedWork W2327375634 @default.
• W3123038875 hasRelatedWork W2330289123 @default.
• W3123038875 hasRelatedWork W2370482371 @default.
• W3123038875 hasRelatedWork W2785875853 @default.
• W3123038875 hasRelatedWork W3029083233 @default.
• W3123038875 hasRelatedWork W3031596504 @default.
• W3123038875 hasRelatedWork W4211239810 @default.
• W3123038875 hasRelatedWork W4310755790 @default.
• W3123038875 hasVolume "39" @default.
• W3123038875 isParatext "false" @default.
• W3123038875 isRetracted "false" @default.
• W3123038875 magId "3123038875" @default.
• W3123038875 workType "article" @default.